<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01749501</url>
  </required_header>
  <id_info>
    <org_study_id>2010-271</org_study_id>
    <nct_id>NCT01749501</nct_id>
  </id_info>
  <brief_title>Premedication for Non-Emergency Endotracheal Intubation In the NICU</brief_title>
  <official_title>Premedication for Non-Emergency Endotracheal Intubation In the NICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin Espinosa, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Gerber Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Those infants who received the muscle relaxation in combination with the vagolytic (reduce
      vagus nerve impulses) and pain medication will have reduced time to successful intubation
      (placement of tube into the lungs), a decrease in the number of attempts, and better
      intubation conditions reported by the practitioner. The objectives of the study include: 1.)
      Does the medication protocol outlined in this study provide optimal intubation conditions?
      (i.e.good jaw relaxation, open and immobile vocal cords and suppression of gag reflex) 2.)
      Does the addition of a muscle relaxant prior to intubation contribute to less attempts and
      achieving successful intubation as opposed to neonates who do not receive the muscle
      relaxant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators project will study two different strategies of pre-medication in an attempt
      to eliminate the pain and discomfort associated with the elective intubation procedure. The
      study will be blinded and patients will be randomized in two different arms according to
      gestational age and identified by study number for pre-medication protocols. Demographic as
      well as study information prior, during and post intubation attempt will be recorded and
      closely monitored. Each patient will be monitored for study purposes for at least 24 hours
      after intubation attempt to record any potential side effects of the medication. The
      investigators plan to have a data safety monitoring board established composed of three
      pediatric doctors / specialists not associated with this study.

      The response of paralysis, onset and duration will be assessed clinically. Onset of muscle
      relaxation will be described as the absence of spontaneous movements and flaccidity, measured
      in seconds from the end of the medication administration. Duration of paralysis will be
      determined by the difference in time from the onset of paralysis to the return of spontaneous
      movements and pre-intubation tone
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Present the Percentage of Participants With an Excellent Ease of Intubation Rating</measure>
    <time_frame>24 hours after intubation period</time_frame>
    <description>percentage of participants with an excellent ease of intubation rating based on Scale of 1-4 (1 Being Excellent, 4 Being Poor),&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timing of Entire Procedure (Stopwatch)and Recording Number of Attempts to Successful Intubation Recorded.</measure>
    <time_frame>24 hours after intubation procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Rocuronium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.6 mg/kg once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>0.6 mg/Kg once</description>
    <arm_group_label>Rocuronium</arm_group_label>
    <other_name>Zemuron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline same amt as 0.6mg/kg of study drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Infants admitted to the NICU at Beaumont Children's Hospital Royal Oak and Troy.

          2. Gestational Age 28 0/7 weeks (or post menstrual age 28 0/7 weeks) or higher

          3. Infants who require endotracheal intubation on a non-emergent basis

          4. Signed informed consent by parents

        Exclusion criteria:

          1. intubations that occurred in the delivery room or for other emergent basis,

          2. absence of intravenous access

          3. abnormality of the airway

          4. known or family history of neuromuscular disorder

          5. renal insufficiency (urine output &lt;0.6 mL/kg per hour or creatine &gt;1.7 mg/dL if &gt; 1
             day of age)

          6. known hepatic insufficiency (abnormal liver function or coagulation laboratory
             results)

          7. Current diagnosis of pulmonary hypertension

          8. Any infant deemed by the attending neonatologist as unstable or unfit for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Espinosa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2012</study_first_posted>
  <results_first_submitted>June 2, 2015</results_first_submitted>
  <results_first_submitted_qc>June 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 22, 2015</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>Martin Espinosa, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>69 participants consented but only 45 needed the study procedure</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Rocuronium</title>
          <description>0.6 mg/kg once
Rocuronium: 0.6 mg/Kg once</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Normal saline same amt as 0.6mg/kg of study drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rocuronium</title>
          <description>0.6 mg/kg once
Rocuronium: 0.6 mg/Kg once</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Normal saline same amt as 0.6mg/kg of study drug</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>post menstrual age (PMA) weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.4" spread="4.47"/>
                    <measurement group_id="B2" value="33.88" spread="3.65"/>
                    <measurement group_id="B3" value="34.62" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Present the Percentage of Participants With an Excellent Ease of Intubation Rating</title>
        <description>percentage of participants with an excellent ease of intubation rating based on Scale of 1-4 (1 Being Excellent, 4 Being Poor),&quot;</description>
        <time_frame>24 hours after intubation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rocuronium</title>
            <description>0.6 mg/kg once
Rocuronium: 0.6 mg/Kg once</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Normal saline same amt as 0.6mg/kg of study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Present the Percentage of Participants With an Excellent Ease of Intubation Rating</title>
          <description>percentage of participants with an excellent ease of intubation rating based on Scale of 1-4 (1 Being Excellent, 4 Being Poor),&quot;</description>
          <units>% reported as excellent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Timing of Entire Procedure (Stopwatch)and Recording Number of Attempts to Successful Intubation Recorded.</title>
        <time_frame>24 hours after intubation procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rocuronium</title>
            <description>0.6 mg/kg once
Rocuronium: 0.6 mg/Kg once</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Normal saline same amt as 0.6mg/kg of study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Timing of Entire Procedure (Stopwatch)and Recording Number of Attempts to Successful Intubation Recorded.</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" spread="5.0"/>
                    <measurement group_id="O2" value="4.95" spread="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rocuronium</title>
          <description>0.6 mg/kg once
Rocuronium: 0.6 mg/Kg once</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Normal saline same amt as 0.6mg/kg of study drug</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Martin Espinosa</name_or_title>
      <organization>William Beaumont Hospital</organization>
      <phone>248-898-0633</phone>
      <email>Martin.espinosa@beaumont.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

